How to Help Your Patients Save Money on Actemra: A Provider's Guide to Savings Programs

Actemra (tocilizumab) is one of the most effective treatments for rheumatoid arthritis, giant cell arteritis, and related conditions — but at a list price of $2,300–$5,000 per month, cost is a major barrier that can derail treatment before it even starts. Proactive financial navigation is now a standard part of specialty prescribing. This guide helps you understand every tool available to support your patients with Actemra affordability.

Understanding Actemra's Cost Landscape

According to Genentech, Actemra's average monthly costs at list price are:

• Actemra IV: $2,308–$4,616 per month depending on dose administered
• Actemra SC: $2,478–$4,956 per month depending on dosing frequency (weekly vs. every other week)

These costs are prior to insurance. Most commercially insured patients pay a fraction of this with manufacturer assistance. Medicare patients face different structures (see below). Understanding this distinction is key to directing patients to the right resources.

Program 1: Actemra Co-pay Program (Commercially Insured Patients)

For patients with commercial (employer-sponsored or individual marketplace) insurance, the Actemra Co-pay Program is the most impactful tool. Eligible commercially insured patients may pay $0 per treatment, with savings of up to $15,000 per calendar year.

Program details:

• Enrollment: Visit racopay.com or call 1-855-722-6729
• Your office can assist patients with enrollment — the process is online and typically quick
• Restrictions: Commercial insurance required; not valid for Medicare, Medicaid, TRICARE, or other government health programs; enrollment runs on a calendar year basis
• Retroactive rebates may be available if a patient paid out-of-pocket before enrolling — encourage early enrollment

Program 2: Genentech Patient Foundation (Uninsured and Underinsured Patients)

For patients without insurance or with financial hardship, the Genentech Patient Foundation provides Actemra at no cost. Eligibility criteria include:

• Household income within program guidelines (linked to federal poverty level; approximately $75,000 for a family of 4 as a benchmark, but verify directly with Genentech)
• Out-of-pocket maximum exceeding 7.5% of household income under current insurance plan

Application process (both forms required):

1. Patient completes and signs the Patient Consent Form (available at genentech-access.com or actemrahcp.com)
2. Prescriber completes and signs the Prescriber Foundation Form
3. Fax or text both completed forms to Genentech
4. Processing takes approximately 5 business days; your office is contacted to discuss next steps

Contact: 1-888-941-3331 (Mon–Fri, 6AM–5PM PST)

Program 3: Genentech Access Solutions

Genentech Access Solutions (1-888-249-4918 / genentech-access.com) is a hub service for insurance navigation, prior authorization support, and specialty pharmacy coordination for Actemra. For your practice, this means:

• Help identifying which payer benefits cover Actemra for a given patient
• Prior authorization support and appeals assistance
• Connecting patients to the co-pay program or Patient Foundation
• An online portal for managing service requests at your practice's convenience

39,333+ patients found their medications in stock

39K+

Find Actemra In Stock Today →

Navigating Biosimilar Cost Advantages in 2026

In 2026, biosimilar cost dynamics have become clinically relevant. Tocilizumab biosimilars (Tofidence, Tyenne, Avtozma) are typically priced lower than brand Actemra, and most payers have placed them on preferred formulary tiers. For patients with high cost-sharing, prescribing a biosimilar may result in meaningfully lower out-of-pocket costs without any clinical compromise.

Key steps:

• Check the patient's payer formulary to identify which tocilizumab product is on the preferred tier
• Review the biosimilar manufacturers' co-pay assistance programs — Fresenius Kabi (Tyenne) and Celltrion (Avtozma) each have patient support programs
• If a patient is already on Actemra and wants to save money, a biosimilar transition may reduce insurance tier cost even if they're not in financial hardship

Medicare and Government-Insured Patients: Alternative Resources

Manufacturer co-pay cards cannot be used with Medicare or Medicaid. For these patients:

• Medicare Part D Out-of-Pocket Cap: In 2026, the cap is $2,100/year for covered medications. This significantly limits Actemra SC exposure for Part D patients.
• Genentech Patient Foundation: Available to Medicare patients who meet income guidelines.
• Extra Help (Low Income Subsidy): Refer eligible Medicare patients to Social Security Administration to apply for Extra Help, which can dramatically reduce Part D costs.
• PAN Foundation: The Patient Access Network Foundation (panfoundation.org) provides assistance to underinsured patients including those on Medicare, subject to fund availability.

Skip the calls, skip the stress.

Find Actemra In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Building a Financial Navigation Workflow in Your Practice

Best practices for integrating financial support into Actemra prescribing:

1. Assign a staff member to screen for assistance program eligibility for every new Actemra prescription
2. Enroll commercially insured patients in the Actemra Co-pay Program before or at the time of the first prescription
3. Verify insurance formulary status for each new patient — document whether brand or biosimilar is preferred
4. Keep program enrollment dates on file — co-pay program enrollment is calendar-year based and requires annual renewal

For supply-related support, see our article on what providers need to know about the Actemra shortage in 2026. To learn how medfinder for providers can support your patients in locating Actemra at pharmacies near them, visit our provider page.